Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Leishmania donovani | farnesyl pyrophosphate synthase | Starlite/ChEMBL | References |
Homo sapiens | farnesyl diphosphate synthase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Toxoplasma gondii | polyprenyl synthetase superfamily protein | 0.0247685 | 0.5 | 0.5 |
Plasmodium falciparum | geranylgeranyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Trichomonas vaginalis | geranylgeranyl diphosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
Trypanosoma brucei | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Giardia lamblia | Farnesyl diphosphate synthase | 0.0247685 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) | 0.0247685 | 0.5 | 0.5 |
Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
Brugia malayi | Polyprenyl synthetase family protein | 0.0247685 | 0.5 | 0.5 |
Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Trypanosoma cruzi | farnesyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
Leishmania major | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Echinococcus multilocularis | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Trypanosoma cruzi | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Plasmodium vivax | geranylgeranyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
Echinococcus granulosus | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
Loa Loa (eye worm) | polyprenyl synthetase | 0.0247685 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = -6.46 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
IC50 (functional) | = -4.3 | Predicted pIC50 against Tryomastigotes Brucei rhodesiense. | ChEMBL. | 12086478 |
IC50 (binding) | = 0.35 uM | Inhibitory activity against Leishmania major Farnesyl diphosphate synthase | ChEMBL. | 14695831 |
IC50 (binding) | = 0.35 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
IC50 (binding) | = 0.35 uM | Inhibitory activity against Leishmania major Farnesyl diphosphate synthase | ChEMBL. | 14695831 |
IC50 (binding) | = 0.35 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
IC50 (functional) | = 4.8 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
IC50 (functional) | = 4.8 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
IC50 (functional) | = 5 uM | Antimicrobial activity against Plasmodium falciparum | ChEMBL. | 20185316 |
IC50 (functional) | = 7.8 uM | Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release | ChEMBL. | 14711309 |
IC50 (functional) | = 41 uM | Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
IC50 (functional) | = 50.6 uM | In vitro growth inhibition of blood-stream-form Trypanosoma brucei rhodesiense Trypomastigotes | ChEMBL. | 12086478 |
IC50 (functional) | = 50.6 uM | In vitro growth inhibition of blood-stream-form Trypanosoma brucei rhodesiense Trypomastigotes | ChEMBL. | 12086478 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
IC50 (functional) | = 200 uM | Antimicrobial activity against Entamoeba histolytica | ChEMBL. | 20185316 |
Ki (binding) | = 0.033 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
Ki (binding) | = 0.033 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
LD50 (ADMET) | > 1148 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
LD50 (ADMET) | > 1148 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
LD50 (ADMET) | > 1149 uM | 50% lethal dose for inhibition of KB cells growth | ChEMBL. | 12086478 |
LD50 (ADMET) | > 1149 uM | 50% lethal dose for inhibition of KB cells growth | ChEMBL. | 12086478 |
Log IC50 (functional) | = 4.3 | Predicted pIC50 against Tryomastigotes Brucei rhodesiense. | ChEMBL. | 12086478 |
Log IC50 (functional) | = 4.39 | pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
Log IC50 (functional) | = 5.11 | pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release | ChEMBL. | 14711309 |
Log IC50 (binding) | = 6.46 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
TI (ADMET) | > 23 | Therapeutic index measured as the ratio of LD50 (KB cells) to IC50 (T.b. rhodesiense) | ChEMBL. | 12086478 |
TI (ADMET) | > 240 | Therapeutic index was expressed as ratio of LD50 for KB cell line to IC50 against Plasmodium falciparum | ChEMBL. | 14695831 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 14695831 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
4 literature references were collected for this gene.